Osteoporosis
From the Journals
Self-reported falls can predict osteoporotic fracture risk
Over an almost 3-year period, about 3.5% of the population experience a major osteoporotic fracture.
From the Journals
Analysis finds no mortality reductions with osteoporosis drugs
A meta-analysis has found no evidence that osteoporosis drugs are associated with a reduction in mortality.
From the Journals
Lower BMD found in patients with severe hemophilia A
The decrease in BMD was correlated with reduced functional ability and body mass index, and vitamin D insufficiency or deficiency.
Latest News
Bisphosphonates improve BMD in pediatric rheumatic disease
Children and adolescents whose chronic rheumatic disease is treated with steroids could benefit from bisphosphonate therapy to improve bone...
From the Journals
Inadequate glycemic control in type 1 diabetes leads to increased fracture risk
Each percentage increase in hemoglobin level was associated with a 7% increase in fracture risk.
From the Journals
Cathepsin Z identified as a potential biomarker for osteoporosis
The level of cathepsin Z mRNA in PBMC preparations could form the basis of a test for osteoporosis
From the Journals
Eldecalcitol may increase bone mineral density in poor responders to bisphosphonates
Among patients with osteoporosis who have diminished long-term response to bisphosphonate therapy, eldecalcitol reduces bone turnover markers.
From the Journals
Osteoporosis, osteoarthritis risk high among cerebral palsy patients
This is the first study to compare these risks using a relatively large cohort of adults with and without cerebral palsy.
From the Journals
Once-weekly teriparatide still achieves bone mineral density gains
From the Journals
Osteoporotic fracture risk appears higher in adults with hemophilia
The risk of osteoporotic fractures following hemophilia increased with time and was significantly higher 5 years after the diagnosis.
Video
Bisphosphonates before denosumab may prevent postdenosumab BMD rebound effect
MADRID – Preliminary results suggest that using denosumab after bisphosphonates for rebound is effective and monitoring bone turnover markers at...